Phase 2 Study of Rademikibart for Acute Asthma Exacerbation Initiated by Connect Biopharm
Connect Biopharm has initiated Phase 2 trial for Rademikibart as an add-on treatment for acute asthma exacerbations.
Asset / Drug
Drug and asset intelligence for Rademikibart with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.